Cloudbreak Pharma Inc. is advancing its Multi Kinase Inhibitor (MKI) platform with promising candidates CBT-001 and CBT-004, targeting pterygium and pinguecula, respectively. These conditions, prevalent among millions, currently lack FDA-approved therapies. In Phase 2 trials, CBT-001 demonstrated a statistically significant reduction in pterygial vascularity (p<0.001) and lesion size (p<0.014), positioning it for potential FDA approval by Q3 2026. CBT-004 also showed clinically meaningful improvements in symptoms associated with pinguecula, setting the stage for a Phase 3 study in early 2027.

The significance of these findings lies in the MKI platform’s unique ability to simultaneously block multiple receptor tyrosine kinases (RTKs), including VEGF, PDGF, and FGF, which are implicated in the inflammatory and fibrotic processes underlying these ocular diseases. Dr. Francis S. Mah emphasizes that this multi-target approach may provide disease-modifying benefits, fundamentally altering the treatment landscape for these common yet serious conditions that affect a substantial patient population.

The implications for the field are substantial. If successful, CBT-001 and CBT-004 could represent the first pharmacologic treatments for pterygium and pinguecula, respectively, potentially reducing reliance on surgical interventions and improving patient outcomes. This advancement not only addresses significant unmet medical needs but also sets a precedent for future drug development targeting similar ocular conditions, thereby influencing research paradigms in ophthalmology and longevity science.

Source: globenewswire.com